Annette Conrads-Frank

Annette Conrads-Frank

Auto-generated profile, based on publicly available information

Annette Conrads-Frank

Institute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT TIROL – University for Health Sciences and Technology, Hall in Tirol, Austria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
ISIgor Stojkov
Igor Stojkov
ACAnnette Conrads-Frank
Annette Conrads-Frank
URUrsula G Rochau
Ursula G Rochau
KKKarin Koinig
Karin Koinig
MAMarjan Arvandi
Marjan Arvandi
RSReinhard Stauder
Reinhard Stauder
Patient-reported outcomes (PROs) are relevant and valuable end points in the care of patients with myelodysplastic syndromes (MDS). However, a consensus-based selection of PROs for MDS, derived by both patients and hematologists, is lacking. We aimed to develop a core set of PROs for patients with MDS as part of the prospective European LeukemiaNet MDS (EUMDS) Registry. According to international guidelines, candidate PROs were identified from a comprehensive literature search of MDS studies. Overall, 40 PROs were selected and evaluated in a two-round Delphi survey by 40 patients with MDS and 38 hematologists in the first round and 38 patients and 32 hematologists in the second round. Based on an agreement scale and predefined inclusion criteria, both patients and hematologists selected “general quality of life” as a core PRO. Hematologists also selected “transfusion-dependency burden” and “ability to work/activities of daily living” as core PROs. The second Delphi round increased PRO rating agreements. Statistically significant rating differences between patients and hematologists were observed for 28 PROs (Mann-Whitney U test; P < .05) in the first round and for 19 PROs in the second round, with “disease knowledge” and “confidence in health care services” rated notably higher by patients. The overall mean PRO ratings correlation between the 2 groups was moderate (Spearman’s rank correlation coefficient = 0.5; P < .05). This first consensus on a core set of PROs jointly developed by patients and hematologists forms the basis for patient-centered care in daily practice and clinical research.

1 January 2025 in Health & Social Care in the Community
Verified
Journal Article
Open access
URUrsula Rochau
Ursula Rochau
VPVeronika Papon
Veronika Papon
ISIgor Stojkov
Igor Stojkov
FKFelicitas Kühne
Felicitas Kühne
MAMarjan Arvandi
Marjan Arvandi
SPSibylle Puntscher
Sibylle Puntscher
Nature‐based social prescribing (NBSP) is an evolving subject aiming to reduce loneliness and to foster social connections, health, and well‐being. To evaluate the short‐term and long‐term consequences of different health technologies, decision‐analytic modeling can be applied. Decision‐analytic modeling studies systematically integrate current short‐ and long‐term evidence to weigh benefits, harms, and costs of different strategies. Our systematic literature review identified and assessed decision‐analytic modeling studies addressing specifically NBSP or other interventions aiming to reduce loneliness. Predefined inclusion/exclusion criteria guided our systematic literature search in five databases. Title/abstract screening and full‐text screening were conducted by two independent reviewers. An a priori defined extraction table included country, intervention, and model type. The Philips framework was used to evaluate the quality of the studies. Overall, 3273 studies were identified, and 16 studies were eligible for full‐text screening. None of these studies applied a decision‐analytic model specifically to NBSP. However, two studies compared interventions for reducing loneliness. One study was conducted in Australia and performed a cost‐utility analysis, resulting in cost‐saving results and a positive return on investment. The second study was conducted in England and applied a cost‐effectiveness analysis resulting in 768 British pounds per loneliness‐free year gained. Overall, the evaluated interventions can be regarded as cost‐effective, and in some instances, they have the potential to save costs. Further research on the connection of loneliness, overall health, social well‐being, and quality of life and their integration into decision‐analytic studies is needed.

14 March 2026 in BMC Primary Care
Verified
Journal Article
Open access
PDF file
SPSibylle Puntscher
Sibylle Puntscher
ISIgor Stojkov
Igor Stojkov
MAMarjan Arvandi
Marjan Arvandi
FKFelicitas Kühne
Felicitas Kühne
ACAnnette Conrads-Frank
Annette Conrads-Frank
URUrsula Rochau
Ursula Rochau
Background: Nature-based social prescribing (NBSP) is a form of social prescribing that can enhance mental and/or physical health by connecting participants with nature through non-medical community referrals. While evidence suggests potential benefits of NBSP in promoting well-being, its economic impact remains unclear. The purpose of our systematic literature review is to investigate the health-economic impact of NBSP programs. Methods: We searched six databases in July 2024. Two reviewers independently screened publications for eligibility: (1) NBSP interventions for health improvement among adults (2), partial or complete economic analyses, and (3) peer-reviewed original studies, published in English, Spanish, or German after the year 2000. Eligible data were systematically extracted by two independent authors into an extraction form including standardized information on the publication, population and setting, compared strategies, details of the analytic framework, main results, limitations, and study conclusions. This information was further synthesized in an evidence table and analyzed using a narrative synthesis approach, with results summarized for each study. The quality of the included studies was assessed using the Consensus Health Economic Criteria list. The review followed PRISMA guideline and is registered on PROSPERO (CRD42021286176). Results: Of the 2,985 hits identified, five studies met the inclusion criteria, all of which were conducted in the United Kingdom (UK) and included people with mild mental and/or physical health issues. The time horizon ranged from twelve weeks to ten years. Three studies conducted a social return on investment (SROI) analysis and reported SROI ratios between 2.6 and 5.1 British pounds (GBP) per GBP invested. One cost-benefit study identified economic returns of 6,000–14,000 GBP per person after one year, with potential returns of up to 8,600 − 24,500 GBP per person after ten years. One cost-utility analysis resulted in costs of 8,600 GBP per quality-adjusted life year gained. Conclusions: Evidence on the health and economic impacts of NBSP is currently limited. The five identified studies, all based in the UK, generally reported favorable health and economic findings. However, the small number of studies, their methodological limitations, and the exclusive UK focus constrain the generalizability of these conclusions. To better inform healthcare decision-making and to implement NBSP programs worldwide, further research on NBSP interventions and their economic impact is needed. Consequently, future studies should explore international settings, incorporate additional data sources, include control groups, and assess longer follow-up periods.

16 August 2004 in Zeitschrift für Gastroenterologie
Verified
Journal Article
Closed access
Uwe SiebertUwe Siebert
Uwe Siebert
GSGaby Sroczynski
Gaby Sroczynski
ACA. Conrads-Frank
A. Conrads-Frank
JWJ. B. Wong
J. B. Wong
SRS. Rossol
S. Rossol
Objective: To assess the public health impact of different antiviral therapies (AVT) for chronic hepatitis C (CHC) when accounting for CHC-related diseases (e.g., HIV/HCV co-infection, haemophilia, history of i.v. drug use). Methods: Design: We used a Markov model, the German Hepatitis C Model (GEHMO) [1], combined with with prevalence and incidence cohort simulation. Data Sources: Pooled efficacy data from clinical trials and literature-based epidemiologic data on CHC and co-morbidities. Target Population: All treatable treatment-naïve German patients with known CHC and elevated ALT levels. Time Horizon: 20 years. Interventions: Initial AVT with peginterferon plus ribavirin (Peg+R), interferon plus ribavirin (IFN+R), interferon monotherapy (IFN), and no AVT (NoAVT). Results: After excluding patients with normal ALT, non-adherence, contraindications, current substance abuse, and previous treatment, 43,000 prevalent cases (11%) and 1,400 incident cases/year (22%) remained in the decision model. Without AVT, the model predicts 20-year cumulative incidences of 29,000 patients with compensated cirrhosis, 16,000 with decompensated cirrhosis, 300 with hepatocellular carcinoma, 1,200 with need for liver transplant, and 16,000 CHC-related deaths. Peg+R can reduce each of these numbers by 47–58% (29–37% for IFN+R, 12–15% for INF). During 20 years, Peg+R saves 53,000 life years or 49,000 QALY. Conclusions: Due to decreasing CHC incidence absolute numbers of patients with compensated cirrhosis are already declining. However, the number of hepatocellular carcinoma, CHC-related deaths, and need for liver transplants is expected to increase for 20 years or more. About half of the morbidity and mortality can be eliminated by treatment with peginterferon and ribavirin. Grant Support: German Federal Ministry of Health and Social Security and German Hepatitis C Coalition [1] Siebert U, Sroczynski G, unter Mitwirkung der German Hepatitis C Model (GEHMO) Group und des HTA-Expertenpanels für Hepatitis C. Antivirale Therapie bei Patienten mit chronischer Hepatitis C in Deutschland. Medizinische und ökonomische Evaluation der initialen Kombinationstherapie mit Interferon / Peginterferon und Ribavirin. Health Technology Assessment Vol 8. Schriftenreihe des DIMDI im Auftrag des Bundesministeriums für Gesundheit und Soziale Sicherung. Köln: DIMDI, 2003; 202 S.